Prexton Therapeutics' Acquisition

Prexton Therapeutics was acquired by H. Lundbeck on March 16, 2018.

Prexton Therapeutics is a biopharmaceutical company which applies a new scientific approach that fully integrates molecular, behavioral and chemistry technologies to address Parkinson's disease and ot…

Articles about Prexton Therapeutics' Acquisition: